Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

Author(s):

Carsten Niemann, MD, PhD,Arnon Kater, MD, PhD

Panelists discuss the role of ven-ibr in patient populations.

Video content above is prompted by the following:

  • What is role of ven-ibr in these patient populations?
  • When may you opt for this approach over other time-limited therapy options (ven-obi) or continuous BTKi therapy?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
March 13th 2025

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
March 10th 2025

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Michael T. Tees, MD, MPH
March 6th 2025

BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression

Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
March 4th 2025

Combination Regimens Expand CLL Treatment Paradigm